6-BROMO-7-CHLOROQUINAZOLINE-2,4-DIOL, 95.0%, 250mg

2-Chloro-4-fluorophenyl cyclopropyl ketone, 97.0%, 1g

tert-butyl 4-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carboxylate, 95.0%, 1g

methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate, 95.0%, 250mg

1-[Tris(1-methylethyl)silyl]-1H-pyrrolo[2,3-b]pyridine, 98%, 1g

4,4-Piperidinediol hydrochloride, 98.0%, 1kg

Berberine hydrochloride, 95.0%, 100g

tert-Butyl 1,6-diazaspiro[3.3]heptane-6-carboxylate oxalate(2:1), 97%, 100mg

2-(1H-Benzoimidazol-2-yl)-2H-[1,2,4]triazol-3-ylamine, 95.0%, 1g

HPLC column NUCLEODUR® 100-5 C8 ec, 150 mm, 4.6 mm, 1 Piece(s)

1-(Phenylmethyl)-2(1H)-pyridinimine, 250mg

Cyclopropyl(naphthalen-1-yl)methanone, 95.0%, 100mg

GC capillary column ROTI®Cap-1, 50 m, 0.20 mm, 0.50 µm, 1 Piece(s)